Contact Us
Drug Search Results
More Filters [+]

Cangrelor

Alternative Names: cangrelor, Kengreal
Latest Update: 2024-12-07
Latest Update Note: Clinical Trial Update

Product Description

Cangrelor (AR-C69931MX) is an intravenous, direct-acting and reversible P2Y(12) receptor antagonist. Cangrelor has a rapid onset and offset of action and achieves significantly greater degrees of platelet inhibition compared with clopidogrel.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19814662/)

Mechanisms of Action: P2Y12 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | Switzerland | Ukraine | United Kingdom | United States

Approved Indications: Coronary Thrombosis | Myocardial Infarction | Thrombosis

Known Adverse Events: Injuries/wounds Unspecified

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cangrelor

Countries in Clinic: France

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Stroke

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
REPERFUSE

P3

Recruiting

Stroke

2026-06-02

Recent News Events

Date

Type

Title

09/12/2023

News Article

 Antiplatelet Drugs Market Size Share, Growth, 2023-2031

05/17/2022

News Article

 Global mTOR Inhibitors Market to Surpass US$ 9,534.5 Million by 2030, Says Coherent Market Insights (CMI)

09/20/2021

News Article

 ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™)

06/29/2020

News Article

 Medicure Announces Positive Results for AGGRASTAT® in the FABOLUS-FASTER Trial and Publication in the Journal - Circulation

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions